<p>New Delhi: Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets.</p>.<p>The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal.</p>.<p>Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing.</p>.Adani Wilmar to invest Rs 600 crore to expand edible oil business, solar power capacities.<p>The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter.</p>.<p>The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal.</p>.<p>Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE. </p>
<p>New Delhi: Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets.</p>.<p>The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal.</p>.<p>Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing.</p>.Adani Wilmar to invest Rs 600 crore to expand edible oil business, solar power capacities.<p>The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter.</p>.<p>The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal.</p>.<p>Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE. </p>